DBV Technologies S.A.
DBVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001613780
No open-market purchases or sales by DBV Technologies S.A. insiders were filed in the last 90 days; 80 institutions reported holding it in 13F filings for Q2 2026, worth $345.9M in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesDBVTF
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 29, 2026, 1:14 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $146.9M (2607.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K/A | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Mar 24, 2025 | Mar 7, 2024 | – | Mar 3, 2022 |
| Revenue | $5.64M | $4.15M | $15.7M | $4.84M | $5.71M |
| Operating expenses | $152.7M | $120.7M | $92.2M | $101.5M | $104.3M |
| Research and development | $116.7M | $89.3M | $60.2M | $75.5M | $70.3M |
| Selling, general and administrative | $32.8M | $28.7M | $29.5M | $24.3M | $30.5M |
| Operating income | -$147.1M | -$116.6M | -$76.4M | -$96.6M | -$98.6M |
| Income tax | $491.0K | $55.0K | $7.00K | $70.0K | -$381.0K |
| Net income | -$146.9M | $113.9M | -$72.7M | -$96.3M | -$97.8M |
| EPS, basic | $-1.05 | $-1.17 | $-0.76 | $-1.24 | – |
| EPS, diluted | $-1.05 | $-1.17 | $-0.76 | $-1.24 | – |
| Weighted shares, basic | 139.6M | 97.0M | 95.1M | 77.4M | – |
| Weighted shares, diluted | 139.6M | 97.0M | 95.1M | 77.4M | – |
| Margins and growth | |||||
| Operating margin | -2609.2% | -2808.7% | -486.0% | -1994.9% | -1727.6% |
| Net margin | -2607.3% | 2744.4% | -462.4% | -1987.5% | -1713.5% |
| Revenue growth, year over year | +35.8% | −73.6% | +224.7% | −15.1% | −49.4% |
| Net income growth, year over year | −229.0% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Mar 24, 2025 | Mar 7, 2024 | – | Mar 3, 2022 |
| Cash and equivalents | $194.2M | $32.5M | $141.4M | $209.2M | $77.3M |
| Accounts receivable | – | – | $0 | $0 | $0 |
| Total current assets | $212.9M | $44.4M | $158.9M | $223.1M | $114.4M |
| Property, plant and equipment | $10.4M | $11.3M | $12.6M | $15.1M | $18.1M |
| Intangible assets | $22.0K | $40.0K | $58.0K | $10.0K | $22.0K |
| Total assets | $233.7M | $65.7M | $183.0M | $246.5M | $146.7M |
| Total current liabilities | $58.0M | $31.1M | $37.3M | $29.5M | $31.4M |
| Total liabilities | $64.9M | $38.3M | $42.8M | $52.1M | $47.4M |
| Shareholders' equity | $168.8M | $27.4M | $140.2M | $194.5M | $99.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 26, 2026 | Mar 24, 2025 | Mar 7, 2024 | – | Mar 3, 2022 |
| Operating cash flow | -$121.2M | -$104.5M | -$79.7M | -$55.7M | -$108.2M |
| Capital expenditures | $532.0K | $2.34M | $677.0K | $754.0K | $910.0K |
| Free cash flow | -$121.7M | -$106.8M | -$80.3M | -$56.4M | -$109.2M |
| Depreciation and amortization | $2.99M | $2.72M | – | – | – |
| Stock-based compensation | $5.39M | $4.62M | $6.02M | $5.03M | $3.12M |
| Investing cash flow | -$1.37M | -$757.0K | -$808.0K | -$100.0K | -$433.0K |
| Financing cash flow | $276.2M | $587.0K | $6.77M | $194.1M | $274.0K |
| Net change in cash | $161.7M | -$108.9M | -$67.8M | $131.9M | -$119.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 95.6% | 111.3% | 38.3% | 103.8% | 54.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 26, 2026 | 314.4M | +85.9% | SEC |
| Jul 16, 2026 | 296.1M | +116.1% | SEC |
| Apr 30, 2026 | 296.0M | +116.2% | SEC |
| Apr 15, 2026 | 296.0M | +116.2% | SEC |
| Mar 25, 2026 | 296.0M | +116.2% | SEC |
| Oct 27, 2025 | 169.1M | +75.2% | SEC |
| Jul 29, 2025 | 137.0M | +41.9% | SEC |
| Apr 30, 2025 | 136.9M | +42.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-5 in Q4 2024.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.